US Phlow Model And Drug Nationalism: Do Indian Firms Need To Be Watchful?
The new US public benefit pharma manufacturing firm Phlow has received significant federal funding in a bid to improve domestic supply security. Scrip speaks to prominent executives in India's industry over whether this model, if widely replicated, could put at risk the clout and market access plans of the Indian generic industry, a major supplier to the US market.
You may also be interested in...
Civica Rx and Kaiser, two non-profit organizations, have announced a partnership to ensure the uninterrupted supply of essential generics to health providers across US during the coronavirus pandemic.
Under generic industry group’s proposal, the federal government would have to pay more for drugs to ensure industry investments in domestic manufacturing pay off.
In a bid to ensure long-term medicines security, the Indian government has earmarked $1.32bn to promote domestic production of 53 APIs, including lopinavir and ritonavir currently being evaluated to treat COVID-19 cases, as well as antibiotics, for which India is highly dependent on China.